It is interesting to compare PBT ($0.2B) to Acadia ($1.9B) when...

It is interesting to compare PBT ($0.2B) to Acadia ($1.9B) when talking about cash needed for trials.

Acadia from their Annual Report for the year ending 31 Dec 2012:

"Risks Related to Our (Acadia) Business
We expect our net losses to continue for at least several years and are unable to predict the extent of future
losses or when we will become profitable, if ever.
We have experienced significant net losses since our inception. As of December 31, 2012, we had an
accumulated deficit of approximately $367.7 million. We expect to incur net losses over the next several years as
we advance our programs and incur significant clinical development costs..."

"...We (Acadia) have consumed substantial amounts of capital since our inception. Our cash, cash equivalents and
investment securities totaled $108.0 million at December 31, 2012. While we believe that our existing cash
resources and anticipated payments from our existing collaborations will be sufficient to fund our cash
requirements into 2015, we will require significant additional financing in the future to continue to fund our
operations..."

IMO it is nice to see PBT keep their cash reserves up.